Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™
Nutriband Inc. (NASDAQ:NTRB) has received a Notice of Allowance from the USPTO for patent application 18/369,241, covering its Aversa™ abuse deterrent technology. This technology is designed to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential in transdermal patches.
The company's lead product, Aversa™ Fentanyl, aims to become the first abuse-deterrent fentanyl transdermal system. The technology utilizes a proprietary aversive agent coating that employs taste aversion to deter oral abuse. The intellectual property is protected by patents in 46 countries, including major markets like the US, Europe, Japan, and China.
According to a market analysis report, Aversa Fentanyl has the potential to achieve peak annual US sales between $80 million to $200 million.
Nutriband Inc. (NASDAQ:NTRB) ha ricevuto un Avviso di Concessione dall'USPTO per la richiesta di brevetto 18/369,241, che riguarda la sua tecnologia Aversa™ per la deterrenza degli abusi. Questa tecnologia è progettata per prevenire abusi, deviazioni, usi inappropriati e esposizioni accidentali a farmaci con potenziale di abuso attraverso cerotti transdermici.
Il prodotto principale dell'azienda, Aversa™ Fentanyl, punta a diventare il primo sistema transdermico di fentanyl a deterrenza degli abusi. La tecnologia utilizza un rivestimento con un agente aversivo proprietario che impiega l'avversione al gusto per dissuadere l'abuso orale. La proprietà intellettuale è protetta da brevetti in 46 paesi, compresi mercati principali come Stati Uniti, Europa, Giappone e Cina.
Secondo un rapporto di analisi di mercato, Aversa Fentanyl ha il potenziale di raggiungere vendite annuali pike negli Stati Uniti tra 80 milioni e 200 milioni di dollari.
Nutriband Inc. (NASDAQ:NTRB) ha recibido un Aviso de Aprobación de la USPTO para la solicitud de patente 18/369,241, que cubre su tecnología Aversa™ para la prevención de abusos. Esta tecnología está diseñada para prevenir abusos, desvío, uso indebido y exposición accidental a medicamentos con potencial de abuso a través de parches transdérmicos.
El producto principal de la empresa, Aversa™ Fentanyl, busca convertirse en el primer sistema transdérmico de fentanilo con deterrencia de abusos. La tecnología utiliza un recubrimiento con un agente aversivo propietario que emplea la aversión al gusto para disuadir el abuso oral. La propiedad intelectual está protegida por patentes en 46 países, incluidos los principales mercados como EE. UU., Europa, Japón y China.
Según un informe de análisis de mercado, Aversa Fentanyl tiene el potencial de alcanzar ventas anuales máximas en EE. UU. entre 80 millones y 200 millones de dólares.
Nutriband Inc. (NASDAQ:NTRB)는 Aversa™ 남용 방지 기술에 관한 특허 출원 18/369,241에 대해 USPTO로부터 허가 통지를 받았습니다. 이 기술은 경피 패치를 통해 남용 가능성이 있는 약물의 남용, 전용, 오용 및 우발적 노출을 방지하도록 설계되었습니다.
회사의 주요 제품인 Aversa™ Fentanyl은 남용 방지형 펜타닐 경피 시스템이 되는 것을 목표로 하고 있습니다. 이 기술은 구강 남용을 방지하기 위해 맛의 회피를 이용하는 독점적인 혐오 물질 코팅을 사용합니다. 지적 재산권은 미국, 유럽, 일본 및 중국과 같은 주요 시장을 포함하여 46개국에서 특허로 보호됩니다.
시장 분석 보고서에 따르면 Aversa Fentanyl은 미국에서 8천만에서 2억 달러 사이의 연간 최대 매출을 달성할 잠재력이 있습니다.
Nutriband Inc. (NASDAQ:NTRB) a reçu un Avis d'Autorisation de l'USPTO pour la demande de brevet 18/369,241, couvrant sa technologie Aversa™ de prévention des abus. Cette technologie est conçue pour prévenir les abus, les détournements, les usages inappropriés et l'exposition accidentelle à des médicaments ayant un potentiel d'abus dans des patchs transdermiques.
Le produit phare de la société, Aversa™ Fentanyl, vise à devenir le premier système transdermique de fentanyl à prévention des abus. La technologie utilise un revêtement d'agent aversif propriétaire qui emploie l'aversion au goût pour dissuader l'abus oral. La propriété intellectuelle est protégée par des brevets dans 46 pays, y compris des marchés majeurs tels que les États-Unis, l'Europe, le Japon et la Chine.
Selon un rapport d'analyse de marché, Aversa Fentanyl a le potentiel d'atteindre des ventes annuelles maximales aux États-Unis entre 80 millions et 200 millions de dollars.
Nutriband Inc. (NASDAQ:NTRB) hat eine Mitteilung über die Erlaubnis vom USPTO für die Patentanmeldung 18/369,241 erhalten, die sich auf die Aversa™ Technologie zur Missbrauchsprävention bezieht. Diese Technologie wurde entwickelt, um Missbrauch, Ablenkung, unsachgemäßen Gebrauch und versehentliche Exposition gegenüber Drogen mit Missbrauchspotential in transdermalen Pflastern zu verhindern.
Das Hauptprodukt des Unternehmens, Aversa™ Fentanyl, hat das Ziel, das erste missbrauchsverhindernde transdermale System für Fentanyl zu werden. Die Technologie verwendet eine proprietäre aversive Beschichtung, die Geschmacksaversion nutzt, um oralen Missbrauch abzuschrecken. Das geistige Eigentum ist durch Patente in 46 Ländern geschützt, darunter wichtige Märkte wie die USA, Europa, Japan und China.
Laut einem Marktanalysebericht hat Aversa Fentanyl das Potenzial, jährliche Höchstverkäufe in den USA zwischen 80 Millionen und 200 Millionen Dollar zu erreichen.
- Patent allowance strengthens intellectual property protection in the US market
- Technology already protected by patents in 46 countries across major markets
- Potential first-mover advantage in abuse-deterrent pain patch market
- Projected peak annual US sales of $80-200 million for Aversa Fentanyl
- Product still under development, not yet commercialized
- Sales projections are estimates with no guarantee of achievement
Insights
The USPTO Notice of Allowance for Nutriband's Aversa™ technology marks a pivotal expansion of their IP fortress. This patent specifically strengthens protection for their abuse-deterrent transdermal system in the world's largest pharmaceutical market. The timing is particularly strategic as the opioid crisis continues to demand innovative solutions.
The patent's broad claims covering 'Abuse and Misuse Deterrent Transdermal Systems' suggest robust protection against potential competitors. With existing patents in 46 countries including major markets like Europe, Japan and China, Nutriband has effectively created significant barriers to entry. This comprehensive IP shield is important for protecting their projected
The technology's unique approach using taste aversion represents a novel solution to a complex problem. This patent allowance strengthens Nutriband's position in negotiations with potential pharmaceutical partners and increases the likelihood of successful commercialization. The market size projection appears conservative given the substantial unmet need for abuse-deterrent opioid delivery systems.
Key strategic implications include:
- Enhanced negotiating position with potential licensees or acquirers
- Reduced risk of competitive entry in key markets
- Stronger position for regulatory approval pathway
- Extended market exclusivity period
Nutriband's Aversa™ technology represents a significant advancement in addressing a critical market gap in transdermal drug delivery safety. The abuse-deterrent features target a pressing healthcare concern, particularly relevant given the ongoing opioid crisis. The potential to become the first abuse-deterrent pain patch creates a unique market position.
The technology's versatility in addressing both opioids and stimulants significantly expands the total addressable market beyond the initial
Market adoption drivers include:
- Growing regulatory pressure for abuse-deterrent formulations
- Healthcare provider preference for safer delivery systems
- Insurance companies' focus on risk mitigation
- Potential for preferred formulary status
The broad geographical patent protection positions Nutriband to capture value across major pharmaceutical markets. The technology's application potential across multiple drug classes suggests significant upside beyond the initial fentanyl market estimates, potentially multiplying the revenue opportunity.
The AVERSA™ transdermal abuse deterrent technology is protected by a broad international intellectual property portfolio with patents already issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia
ORLANDO, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on February 3, 2025 for patent application 18/369,241, "Abuse and Misuse Deterrent Transdermal Systems" which covers its Aversa™ abuse deterrent technology. The receipt of a Notice of Allowance means that the USPTO is expected to issue a U.S. patent for this application after administrative processes have been completed.
The expected issuance of this patent further expands Nutriband’s intellectual property protection in the United States for its portfolio of abuse deterrent transdermal products based on its proprietary Aversa™ abuse deterrent technology. This technology can be incorporated into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. Nutriband’s lead product under development is Aversa™ Fentanyl, an abuse deterrent fentanyl transdermal system, with the potential to become the first and only abuse deterrent pain patch on the market.
Nutriband’s AVERSA™ abuse-deterrent technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products.
The AVERSA™ abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
AVERSA Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA Fentanyl has the potential to reach peak annual US sales of
____________________________________________
1 Health Advances Aversa Fentanyl market analysis report 2022
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words "believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2024, filed May 1, 2024, the Forms 10-Q’s filed subsequent to the Form 10-K in 2024, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: Support@nutriband.com
SOURCE: Nutriband Inc.
FAQ
What is the potential market value for Nutriband's (NTRB) Aversa Fentanyl product?
How many countries have granted patents for NTRB's Aversa technology?
What is the significance of NTRB's recent USPTO Notice of Allowance?
How does Nutriband's (NTRB) Aversa abuse-deterrent technology work?
